Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nuvo Pharmaceuticals Inc. (T:NRI)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for NRI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 17, 2019 08:00 ET
Nuvo Pharmaceuticals™ Provides Corporate Update
MISSISSAUGA, ON, June 17, 2019 /CNW/ - Nuvo Pharmaceuticals Inc. ("Nuvo" or "the Company") (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided a corporate update on various matters including its VIMOVO patents, the identification of Aralez Transaction synergies and an update regarding the status of its financing arrangements with Deerfield Management Company, L.P. (Deerfield). All financial references are in Canadian dollars unless otherwise indicated.
Read full article
May 15, 2019 13:25 ET
IIROC Trade Resumption - NRI
TORONTO, May 15, 2019 /CNW/ - Trading resumes in:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.01
--
--
Price to Sales - TTM
0.51
8.84
16.65
Price to Book - most recent quarter
0.49
3.06
3.27
Price to Cash Flow per share - TTM
--
10.06
12.71
Price to Free Cash Flow per share - TTM
--
9.15
11.76
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 31, 2019110,945110,445
May 15, 2019500-1,914
Apr 30, 20192,4142,009
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Nuvo Pharmaceuticals Inc, formerly Nuvo Research Inc, is a Canada-based healthcare company. The Company offers a range of commercial products, including Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine (HLT) patch. The Company's Pennsaid 2% is a non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium. Its Pennsaid 2% is indicated for treating the pain of osteoarthritis (OA) of the knee and also acute strains and sprains. The Company's Pennsaid is a topical pain product, which is used to treat the signs and symptoms of OA of the knee. The Pennsaid combines the transdermal carrier with diclofenac sodium, which is a NSAID and delivers the active drug through the skin at the site of pain. Its HLT Patch is a topical patch that combines lidocaine, tetracaine and heat, using Controlled Heat-Assisted Drug Delivery (CHADD) technology. HLT Patch provides local analgesia prior to painful needle procedures, such as dialysis, blood draws and pediatric needles.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $NRI.CA

  • No tweets found

StockTwits

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $NRI.CA

  • No tweets found

StockTwits